acute myocardial infarction

PRAGUE 19: bioabsorbable platform for patients with ST segment elevation

Absorbable bioplatforms are considered safe and effective in stable patients but their use in the context of acute myocardial infarction with ST segment elevation has not been reported. Low risk of heart attack with low Killip classification could be the stage for this device. 87 consecutive patients experiencing myocardial infarction with ST elevation underwent primary<a href="https://solaci.org/en/2015/06/24/prague-19-bioabsorbable-platform-for-patients-with-st-segment-elevation/" title="Read more" >...</a>

Hokusai-VTE: Endoxaban shows solid results versus warfarin in venous thromboembolism .

The venous thromboembolism is the third most common cardiovascular disease after acute myocardial infarction and stroke . Usual treatment is to use low molecular weight heparin followed by vitamin K antagonists Other studies have shown that the new oral anticoagulants with or without initial heparin are effective alternatives. The endoxaban is a direct Factor Xa<a href="https://solaci.org/en/2015/06/24/hokusai-vte-endoxaban-shows-solid-results-versus-warfarin-in-venous-thromboembolism/" title="Read more" >...</a>

Impella 2.5 improves survival in AMI with cardiogenic shock

Original title:&nbsp;The Use of Impella 2.5 in Severe Refractory Cardiogenic Shock Complicating and Acute Myocardial Infarction.&nbsp;Reference:&nbsp;Frederic Casassus et al. J Interv Cardiol. 2015 Feb;28(1):41-50. The presence of cardiogenic shock is observed in 7% of patients undergoing acute myocardial infarction (AMI) with ST segment elevation and 2.5% of those with non-ST AMI. In this scenario inotropic<a href="https://solaci.org/en/2015/04/29/impella-2-5-improves-survival-in-ami-with-cardiogenic-shock/" title="Read more" >...</a>

Clinical presentation of restenosis in the three generations of DES

Original title:&nbsp;Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations.&nbsp;Reference:&nbsp;Marco A. Magalhaes et al. Circ Cardiovasc Interv. 2014;7:00-00. Studies evaluating the clinical presentation of restenosis after implantation of bare metal stent showed that the recurrence of stenosis is not a benign complication as previously thought, with a significant number of patients with restenosis<a href="https://solaci.org/en/2015/04/28/clinical-presentation-of-restenosis-in-the-three-generations-of-des/" title="Read more" >...</a>

PCI with everolimus eluting stent or CABG for multivessel coronary artery disease.

Original title:&nbsp;Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease.&nbsp;Reference:&nbsp;Sripal Bangalore, M.D. et al. N Engl J Med. 2015 Mar 26;372(13):1213-22. Coronary artery bypass grafting (CABG) have had better outcomes than percutaneous coronary intervention (PCI) in the treatment of multivessel coronary disease. &nbsp;However, this information comes from studies that do not include new generation stents.<a href="https://solaci.org/en/2015/04/09/pci-with-everolimus-eluting-stent-or-cabg-for-multivessel-coronary-artery-disease/" title="Read more" >...</a>

Zotarolimus eluting stent with one month of dual antiplatelet therapy

Original title:&nbsp;Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates.&nbsp;Reference:&nbsp;Marco Valgimigli et al. J Am Coll Cardiol. 2015;65(8):805-815. The use of drug eluting stents (DES) in patients at high risk of bleeding or thrombosis has not been studied prospectively. Data on patients at high risk of bleeding and low restenosis are limited. This study compared<a href="https://solaci.org/en/2015/02/25/zotarolimus-eluting-stent-with-one-month-of-dual-antiplatelet-therapy/" title="Read more" >...</a>

Enoxaparin appears superior to unfractionated heparin in patients undergoing primary angioplasty

Original title:&nbsp;A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).&nbsp;Reference:&nbsp;Collet et al. Am J Cardiol. 2013; Epub ahead of print. ATOLL study analysis suggests that enoxaparin is superior to unfractionated heparin in reducing ischemic events and mortality in patients&nbsp; suffering ST elevation acute myocardial infarction (STEMI)<a href="https://solaci.org/en/2013/09/16/enoxaparin-appears-superior-to-unfractionated-heparin-in-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>

Does the systematic use of clopidogrel reduce events prior to angioplasty?

Original title:&nbsp;Association of Clopidogrel Pretreatment with mortality, Cardiovascular events, and Major Bleeding among patients undergoing percutaneous coronary intervention. A systematic review and Mata-analysis.&nbsp;Reference:&nbsp;Anne Bellemain-Appaix, MD et al. for the ACTION group. The loading of clopidogrel before coronary angioplasty is an accepted practice by most clinical and interventional cardiologists but, nevertheless, it is only based on<a href="https://solaci.org/en/2013/01/02/does-the-systematic-use-of-clopidogrel-reduce-events-prior-to-angioplasty/" title="Read more" >...</a>

Self-expanding stents improve positioning in primary angioplasty

Original title:&nbsp;Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results From the APPOSITION II Study&nbsp;Reference:&nbsp;Robert-Jan van Geuns et al. J Am Coll Cardiol Intv 2012;5:1209&ndash;19 Acute myocardial infarction is associated with vasoconstriction and thrombus occlusion. Resolution of these two points during the first hours after primary angioplasty can lead to poor extension and poor positioning<a href="https://solaci.org/en/2012/12/21/self-expanding-stents-improve-positioning-in-primary-angioplasty/" title="Read more" >...</a>

ULTIMATE III: Use of IVUS for Coronary De Novo Lesion Drug Coated Balloon Angioplasty

Percutaneous coronary intervention (PCI) with drug eluting stents (DES) can present limitations, especially in the form of stent thrombosis or instent restenosis (ISR). These findings have furthered the development of drub coated balloons (DCB). The safety and efficacy of DCB have already been shown in the context of ISR and de novo small vessel coronary<a href="https://solaci.org/en/2024/07/12/ultimate-iii-use-of-ivus-for-coronary-de-novo-lesion-drug-coated-balloon-angioplasty/" title="Read more" >...</a>

Top